Proactive Investors Interview – Algernon Pharmaceuticals files a pre-IND meeting request with US FDA for Ifenprodil Small Cell Lung Cancer Study

September 24, 2021

Proactive Investors Interview – Algernon Pharmaceuticals files a pre-IND meeting request with US FDA for Ifenprodil Small Cell Lung Cancer Study

 
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.
Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals - All Rights Reserved

Hit enter to search or ESC to close

Share via
Facebook
Twitter
LinkedIn
Mix
Email
Print
Copy Link
Powered by Social Snap
Copy link
CopyCopied
Powered by Social Snap